Anstelai obtains the exclusive right to sell the antiallergic drug ALOC in China

Astaire Pharmaceutical (China) Co., Ltd announced in Beijing on January 16 that Astaire China and Xiehe fermentation Kirin Co., Ltd officially signed an agreement Astaire China has obtained the exclusive right to sell the antiallergic drug alopec (chemical name: orotadine hydrochloride) in China since January 1, 2014 Alopec, independently developed by kylin, is a new type of antihistamine drug It is the first anti allergic drug approved in Japan for the treatment of erythema multiforme exudative It was marketed in China in 2011 with 5mg tablets and approved in China for the treatment of allergic rhinitis, urticaria and pruritus (eczema, dermatitis, pruritus, pruritus, psoriasis vulgaris and pleomorphism) Exudative erythema) For this cooperation, Mr Heitian Changli, general manager of anstar China, has great expectations He believes that with the focus and experience of anstar China in the field of Dermatology, he is confident to bring aloche, a new oral anti allergy preparation, to more patients in need, and help them to alleviate the problems of allergic skin diseases and return to normal life and work as soon as possible Based on the requirements of the framework agreement, after obtaining the sub packaging license, Ansteel China will start the sales of ALOC in the Chinese market Anstelai Pharmaceutical Group is a R & D-oriented enterprise which is headquartered in Tokyo, Japan and develops, produces and sells innovative pharmaceutical products worldwide Astaire China is a wholly-owned subsidiary of its investment in China With the outstanding performance of the immunosuppressant Proctor, BPH and OAB, anstar has been the world leader in transplantation and urology.